SCM
RIGL icon

Sterling Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Sterling Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.5K Sell
371
-563
-60% -$17.4K ﹤0.01% 2038
2026
Q1 		$25.3K Sell
934
-478
-34% -$16.1K ﹤0.01% 1916
2025
Q4 		$60.5K Buy
1,412
+1,369
+3,184% +$51.6K ﹤0.01% 1732
2025
Q3 		$1.22K Hold
43
– – ﹤0.01% 3052
2025
Q2 		$805 Sell
43
-41
-49% -$777 ﹤0.01% 3092
2025
Q1 		$1.51K Sell
84
-57
-40% -$1.16K ﹤0.01% 2679
2024
Q4 		$2.37K Buy
141
+115
+442% +$2.21K ﹤0.01% 2737
2024
Q3 		$421 Buy
+26
New +$306 ﹤0.01% 2938

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sterling Capital Management's RIGL Position: Q2 2026 in Review

Sterling Capital Management reduced its Rigel Pharmaceuticals (RIGL) stake by 60% in Q2 2026, selling an estimated $17.4K and leaving 371 shares worth $14.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2038.

Sterling Capital Management first reported a position in RIGL in Q3 2024 and has held it in 8 quarters since. The position peaked at $60.5K in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Sterling Capital Management held 371 shares of Rigel Pharmaceuticals worth $14.5K as of Q2 2026.
  • Sterling Capital Management sold 563 Rigel Pharmaceuticals shares in Q2 2026, an estimated $17.4K.
  • Rigel Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2038 holding.
  • Sterling Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Rigel Pharmaceuticals position peaked at $60.5K in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.